Enhancement of susceptibility to Fas-mediated apoptosis in oral squamous cell carcinoma cells by phosphatidylinositol 3-kinase inhibitor

Oral Oncology

Volumn 42, Issue 7, 2006, Pages 745-752

  Kondo, Gen ^a   Iwase, Masayasu ^a   Watanabe, Hitoshi ^a   Uchida, Makiko ^a   Takaoka, Sayaka ^a   Ohashi, Masaru ^a   Nagumo, Masao ^a  

^a SHOWA UNIVERSITY SCHOOL OF DENTISTRY   (Japan)

Author keywords

Apoptosis; c FLIP; Fas; PI 3 K; Squamous cell carcinoma

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ANTISENSE OLIGONUCLEOTIDE; CASPASE 3 INHIBITOR; CASPASE 8 INHIBITOR; FAS ANTIGEN; FLICE INHIBITORY PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN KINASE B; WORTMANNIN;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER RESISTANCE; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; MOUTH CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANDROSTADIENES; ANTIGENS, CD95; APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CASP8 AND FADD-LIKE APOPTOSIS REGULATING PROTEIN; CHROMONES; DOWN-REGULATION; ENZYME INHIBITORS; FLOW CYTOMETRY; HUMANS; MORPHOLINES; MOUTH NEOPLASMS; ONCOGENE PROTEIN V-AKT; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 33746220346     PISSN: 13688375     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2005.11.015     Document Type: Article

References (42)

1. Jarpe M.B., Widmann C., Knall C., Schlesinger T.K., Gibson S., Yujiri T., et al. Anti-apoptotic versus pro-apoptotic signal transduction: checkpoints and stop signs along the road to death. Oncogene 17 11 (1998) 1475-1482
2. Nagata S. Apoptosis by death factor. Cell 88 3 (1997) 355-365
3. Peter M.E., and Krammer P.H. Mechanisms of CD95 (APO-1/Fas)-mediated apoptosis. Curr Opin Immunol 10 5 (1998) 545-551
4. Gratas C., Tohma Y., Bamas C., Taniere P., Hainaut P., and Ohgaki H. Up-regulation of Fas (APO-1/CD95) ligand and down-regulation of Fas expression in human esophageal cancer. Cancer Res 58 10 (1998) 2057-2062
5. Moers C., Warskulat U., Muschen M., Even J., Niederacher D., Joeien R., et al. Regulation of CD95 (Apo-1/Fas) ligand and receptor expression in squamous-cell carcinoma by interferon-γ and cisplatin. Int J Cancer 80 4 (1999) 564-572
6. Iwase M., Watanabe H., Kondo G., Ohashi M., and Nagumo M. Enhanced susceptibility of oral squamous cell carcinoma cell lines to Fas-mediated apoptosis by cisplatin and 5-fluorouracil. Int J Cancer 106 4 (2003) 619-625
7. Boldin M.P., Varfolomeev E.E., Pancer W.Z., Mett I.L., Camonis J.H., and Wallach D. A novel protein that interacts with the death domain of Fas/APO-1 contains a sequence motif related to the death domain. J Biol Chem 270 14 (1995) 7795-7798
8. Chinnaiyan A.M., O'Rourtke K., Tewari M., and Dixit V.M. FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell 81 4 (1995) 505-512
9. Thornberry N.A., and Lazebnik Y. Caspases: enemies within. Science 281 5381 (1998) 1312-1316
10. Ashkenazi A., and Dixit V.M. Death receptors: signaling and modulation. Science 281 5381 (1998) 1305-1308
11. Irmler M., Thome M., Hahne M., Schneider P., Hofmann K., Steiner V., et al. Inhibition of death receptor signals by cellular FLIP. Nature 388 6638 (1997) 190-195
12. Krueger A., Baumann S., Krammer P.H., and Kirchhoff S. FLICE-inhibitory proteins: regulators of death receptor-mediated apoptosis. Mol Cell Biol 21 24 (2001) 8247-8254
13. Scaffidi C., Schmitz I., Krammer P.H., and Peter M.E. The role of c-FLIP in modulation of CD95-induced apoptosis. J Biol Chem 274 3 (1999) 1541-1548
14. Ryu B.K., Lee M.G., Chi S.G., Kim Y.W., and Park J.H. Increased expression of cFLIP (L) in colonic adenocarcinoma. J Pathol 194 1 (2001) 15-19
15. Poulaki V., Mitsiades N., Romero M.E., and Tsokos M. Fas-mediated apoptosis in neuroblastoma requires mitochondrial activation and is inhibited by FLICE inhibitor protein and Bcl-2. Cancer Res 61 12 (2001) 4864-4872
16. Kataoka T., Ito M., Budd R.C., Tschopp J., and Nagai K. Expression level of c-FLIP versus Fas determines susceptibility to Fas ligand-induced cell death murine thymoma EL-4 cells. Exp Cell Res 273 2 (2002) 256-264
17. Rippo M.R., Moretti S., Vescovi S., Tomasetti M., Orecchia S., Amici G., et al. FLIP overexpression inhibits death receptor-induced apoptosis in malignant mesothelial cells. Oncogene 14 47 (2004) 7753-7760
18. Datta S.R., Brunet A., and Greenberg M.E. Cellular survival: a play in three Akts. Genes Dev 13 22 (1999) 2905-2927
19. Wendel H.G., De Stanchina E., Fridman J.S., Malina A., Ray S., Kogan S., et al. Survival signaling by Akt and elF4E in oncogenesis and cancer therapy. Nature 428 6980 (2004) 332-337
20. Bao S., Ouyang G., Bai X., Huang Z., Ma C., Liu M., et al. Periostin potently promotes metastatic growth of colon cancer by augmenting cell survival via the Akt/PKB pathway. Cancer Cell 5 4 (2004) 329-339
21. Dudek H., Datta S.R., Franke T.F., Birnbaum M.J., Yao R., Cooper G.M., et al. Regulation of neuronal survival by the serine-threonine protein kinase Akt. Science 275 5300 (1997) 661-665
22. Häusler P., Papoff G., Eramo A., Reif K., Cantrell D.A., and Rubert G. Protection of CD95-mediated apoptosis by activation of phosphatidylinositide 3-kinase and protein kinase B. Eur J Immunol 28 1 (1998) 57-69
23. Nesterov A., Lu X., Johnson M., Miller G.J., Ivashchenko Y., and Kraft A.S. Elevated AKT activity protects the prostate cancer cell line LNCaP from TRAIL-induced apoptosis. J Biol Chem 276 14 (2001) 10767-10774
24. Chen X., Thakkar H., Tyan F., Gim S., Robinson H., Lee C., et al. Constitutively active Akt is an important regulator of TRAIL sensitivity in prostate cancer. Oncogene 20 42 (2001) 6073-6083
25. Kandasamy K., and Srivastava R.K. Role of the phosphatidylinositol 3′-kinase/PTEN/Akt kinase pathway in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in non-small cell lung cancer cells. Cancer Res 62 17 (2002) 4929-4937
26. Panka D.J., Mano T., Suhara T., Walsh K., and Mier J.W. Phosphatidylinositol 3-kinase/Akt activity regulates c-FLIP expression in tumor cells. J Biol Chem 276 10 (2001) 6893-6896
27. Suhara T., Mano T., Oliverira B.E., and Walsh K. Phosphatidylinositol 3-kinase/Akt signaling controls endothelial cell sensitivity to Fas-mediated apoptosis via regulation of FLICE-inhibitory protein (FLIP). Circ Res 89 1 (2001) 13-19
28. Nam S.Y., Jung G.A., Hur G.C., Chung H.Y., Kim W.H., Seol D.W., et al. Upregulation of FLIP (S) by Akt, a possible inhibition mechanism of TRAIL-induced apoptosis in human gastric cancers. Cancer Sci 94 12 (2003) 1066-1073
29. Mitsiades C.S., Mitsiades N., Poulaki V., Schlossman R., Akiyama M., Chauhan D., et al. Activation of NF-κB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications. Oncogene 21 37 (2002) 5673-5683
30. Watanabe H., Iwase M., Ohashi M., and Nagumo M. Role of interleukin-8 secreted from human oral squamous cell carcinoma cell lines. Oral Oncol 38 7 (2002) 670-679
31. Micheau O., Solary E., Hammann A., Martin F., and Dimanche-Boitrel M.T. Sensitization of cancer cells treated with cytotoxic drugs Fas-mediated cytotoxicity. J Natl Cancer Inst 89 11 (1997) 783-789
32. Ferreira C.G., Span S.W., Peters G.J., Kruyt F.A.K., and Giaccone G. Chemotherapy triggers apoptosis in a caspase-8-dependent and mitochondria-controlled manner in the non-small cell lung cancer cell line NCI-H460. Cancer Res 60 24 (2000) 7133-7141
33. Yamamoto T., Yoneda K., Ueta E., Doi S., and Osaki T. Enhanced apoptosis of squamous cell carcinoma cells by interleukin-2-activated cytotoxic lymphocytes combined with radiation and anticancer drugs. Eur J Cancer 36 15 (2000) 2007-2017
34. Medema J.P., de Jong J., van Hall T., Melief C.J.M., and Offringa R. Immune escape of tumors in vivo by expression of cellular FLICE-inhibitory protein. J Exp Med 190 7 (1999) 1033-1038
35. Kinoshita H., Yoshikawa H., Shiiki K., Hamada Y., Nakajima Y., and Tasaka K. Cisplatin (CDDP) sensitizes human osteosarcoma cell to Fas/CD95-mediated apoptosis by down-regulating FLIP-L expression. Int J Cancer 88 6 (2000) 986-991
36. Brognard J., Clark A.S., Ni Y., and Dennis P.A. Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res 61 10 (2001) 3986-3997
37. Nakashio A., Fujita N., Rokudai S., Sato S., and Tsuruo T. Prevention of phosphatidylinositol 3′-kinase-Akt survival signaling pathway during topotecan-induced apoptosis. Cancer Res 60 18 (2000) 5303-5309
38. Tenzer A., Zingg D., Rocha S., Hemmings B., Fabbro D., Glanzmann C., et al. The phosphatidylinositide 3′-kinase/Akt survival pathway is a target for the anticancer and radiosensitizing agent PKC412, an inhibitor of protein kinase C. Cancer Res 61 22 (2001) 8203-8210
39. Shingu T., Yamada K., Hara N., Moritaka K., Osago H., Terashima M., et al. Synergistic augmentation of antimicrotubule agent-induced cytotoxicity by phosphainositide 3-kinase inhibitor in human malignant glioma cells. Cancer Res 63 14 (2003) 4044-4047
40. Hu L., Hofmann J., Lu Y., Mills G.B., and Jaffe R.B. Inhibition of phosphatidylinositol 3′-kinase increases efficacy of paclitaxel in vitro and in vivo ovarian cancer models. Cancer Res 62 4 (2002) 1087-1092
41. Chang D.W., Xing Z., Pan Y., Algeciras-Schimnich A., Barnhart B.C., Yaish-Ohad S., et al. c-FLIP (L) is a dual function regulator for caspase-8 activation and CD95-meditaed apoptosis. EMBO J 21 14 (2002) 3704-3714
42. Micheau O., Thome M., Schneider P., Holler N., Tschopp J., Nicholson D.W., et al. The long form of FLIP is an activator of caspase-8 at the Fas death-inducing signaling complex. J Biol Chem 277 47 (2002) 45162-45171